Management of Medical Emergencies

Board takeaway

• Immediate priorities: Stop dental treatment, call for help, assess airway, breathing, and circulation, and bring oxygen, the emergency kit, and resuscitation equipment.
• Support and escalate: Start the required supportive care and activate emergency medical services promptly for serious deterioration.
• Principle: A rescue drug supplements ventilation and circulatory support.
• Anaphylaxis: For anaphylaxis with breathing or circulatory compromise, give intramuscular epinephrine promptly; an antihistamine is not the first intervention.
• Respiratory depression: For sedative-associated respiratory depression, support ventilation while considering reversal and arrange continued observation.
• Source limits: The compact AAPD chart contains source-specific regimens and several conflicts with specialty guidance or product labeling, identified below.

Decision map: recognition comes before drug selection

Loading diagram…

This map is an initial recognition aid, not a complete resuscitation algorithm. Stop care, assess ABC, summon help, and provide indicated rescue without waiting for EMS. Stable patients still need syndrome-specific assessment and monitoring. The resource chart and current external protocols differ in several places, so preserve the drug/route caveats below rather than silently substitute them.

Allergy: mild reaction versus anaphylaxis

• Mild/delayed pattern: itching, hives, swelling, or redness involving skin, mucosa, or conjunctiva.
  • Remove the suspected allergen sources.
  • Give oral diphenhydramine according to the manufacturer's age/weight instructions; the chart supplies no fixed dose.
• Anaphylaxis pattern: abrupt allergic symptoms with wheezing, bronchospasm, laryngeal swelling, breathing difficulty, weak pulse, major blood-pressure fall, or unconsciousness. Flushing, hives, itching, and rhinitis also may occur.
  • Activate EMS, administer epinephrine and oxygen, monitor vital signs, and arrange emergency-facility transport by advanced responders.
  • Epinephrine 1 mg/mL: 0.01 mg/kg IM; maximum 0.3 mg in a prepubertal child, 0.5 mg in a teen/adult.
  • Inject into the mid-outer thigh; change sites for repeat injections.
  • If unresponsive, the chart permits repetition every 5 minutes, total 3 injections, until recovery or EMS arrival.
  • Alternative: epinephrine autoinjector using manufacturer instructions.

Acute asthma

• Recognize dyspnea, wheezing, coughing, chest tightness, cyanosis, or tachycardia.
• Position upright or comfortably; give oxygen.
• The chart directs a bronchodilator for a single symptom: patient’s or emergency-kit albuterol inhaler, 4–8 puffs, repeated every 20 minutes for 2 additional doses.
• Use a spacer; add a mask when the patient cannot form a lip seal.
• If the bronchodilator fails, or symptoms are severe or multiple, the chart directs epinephrine:
  • 1 mg/mL, 0.01 mg/kg IM; maximum 0.3 mg prepubertal, 0.5 mg teen/adult.
  • Repeat every 5–15 minutes, up to 3 administrations as needed; mid-outer thigh, different sites for repeats.
  • Autoinjector alternative: manufacturer instructions.
• Activate EMS and arrange advanced-care transport when indicated. These are the source’s specific escalation instructions; the chart does not define severity numerically.
• External current-guidance distinction: GINA 2026 does not recommend epinephrine routinely for asthma exacerbations without anaphylaxis. The AAPD escalation above is a source summary; verify the current asthma emergency protocol rather than applying it as a universal rule.

Local anesthetic emergencies

• Toxicity clues: light-headedness, altered vision/speech, metallic taste, tinnitus, confusion/agitation, tremor, seizure, rapid breathing, bradycardia, unconsciousness, or arrest.
  • Assess/support airway, breathing, and circulation; CPR if warranted.
  • Give supplemental oxygen by mask, monitor vital signs, and use EMS/advanced-care transport when indicated.
  • Source contact: Poison Control, 1-800-222-1222.
• Vasoconstrictor reaction clues: anxiety, restlessness, palpitations/tachycardia, headache, rapid breathing, chest pain, or arrest.
  • Reassure; provide the same airway, breathing, circulation, oxygen, monitoring, and conditional EMS support.
• The chart gives no toxic-dose threshold or additional drug regimen for either reaction.

Sedative/opioid overdose

• Shared priorities: support airway, breathing, and circulation; CPR if warranted; oxygen; vital-sign monitoring; EMS and advanced transport when indicated.

Benzodiazepine overdose

• Somnolence, confusion, reduced reflexes, respiratory depression, apnea, or respiratory/cardiac arrest.
• AAPD chart: for severe respiratory depression, establish IV access and reverse with flumazenil 0.01 mg/kg, maximum 0.2 mg per dose.
• May repeat at 1-minute intervals; cumulative maximum is 0.05 mg/kg or 1 mg, whichever is less.
• Route conflict: the AAPD chart lists IV, with IM if IV access is unavailable; current product labeling specifies IV only. Do not infer an IM regimen from this chart; verify the product and emergency protocol.
• External label safety: flumazenil can precipitate seizures, especially with benzodiazepine dependence or mixed overdose.
  • Contraindications include hypersensitivity to flumazenil/benzodiazepines, benzodiazepines used to control a life-threatening condition (eg, status epilepticus), and signs of serious cyclic-antidepressant overdose.
  • Pediatric labeling covers conscious-sedation reversal at ages 1–17; safety/efficacy are not established for pediatric overdose or conscious-sedation reversal below age 1 (DailyMed label).
• Label administration detail (conscious-sedation reversal): give the initial IV dose over 15 seconds, wait 45 more seconds, then repeat if needed at 60-second intervals, up to four additional doses, within the same cumulative ceiling. The label’s indication names ages 1–17, while its dosing paragraph says greater than 1 year; do not silently resolve that exact-age boundary. Repeated treatment for pediatric resedation is not established. DailyMed flumazenil label.
• Observe recovery for at least 2 hours after the last flumazenil dose.

Narcotic/opioid overdose

• Reduced responsiveness and respiratory depression, potentially progressing to respiratory/cardiac arrest.
• For severe respiratory depression, give naloxone 0.1 mg/kg, up to 2 mg via IV, IM, or subcutaneous delivery.
• Repeat as needed to sustain reversal; chart cumulative ceiling 10 mg.
• Alternative: intranasal naloxone according to manufacturer instructions; alternate nostrils if repeating.
• Observe recovery for at least 2 hours after the last naloxone dose.
• The chart does not detail reversal-agent contraindications or define discharge readiness beyond its minimum monitoring interval.

Seizure

• Possible warning signs: disorientation, blinking, or a vacant stare. Seizure findings include uncontrolled movements, rigidity, and unconsciousness.
• Postictal sleepiness, confusion, amnesia, and slow recovery may follow.
• Recline and protect against injury; preserve an open airway and adequate ventilation; monitor vital signs.
• For status epilepticus, the chart lists rescue medication options:
  • Patient’s previously prescribed rescue medication; or
  • Diazepam 5 mg/mL: 0.15–0.2 mg/kg IV, maximum 10 mg; may repeat once. Prefilled rectal/nasal delivery products are also noted; follow their package dosing.
  • Midazolam 0.2 mg/kg, maximum 10 mg, via IM, intranasal, or IV delivery.
• CDC first-aid EMS triggers: seizure lasting longer than five minutes, another seizure soon afterward, trouble breathing or waking afterward, injury, or a first seizure. Also call for a seizure in water, pregnancy, or diabetes with loss of consciousness.
• Use the prescribed rescue plan: follow any earlier activation trigger. These are first-aid EMS criteria, not a definition of status epilepticus or a rescue-drug dosing rule.

CDC First Aid for Seizures, May 15, 2024. The AAPD medication chart does not define a status-duration threshold.

Syncope

• Typical sequence: warmth, dizziness, pale/moist skin, initially fast pulse becoming slow/weak, hypotension, cold extremities, and possible unconsciousness.
• Recline with feet elevated; loosen restrictive clothing; give oxygen and monitor recovery.
• The 2025 chart also lists inhaled ammonia from vials and a cold towel on the posterior neck.
  • It provides no ammonia dose or contraindications; these entries require current protocol/product verification before clinical use.
  • External safety context: FDA’s ammonia-inhalant alert concerns unapproved alertness/energy products and notes risks including airway constriction and irritation; it does not validate the chart’s syncope use.

Medication/device readiness

• Prefilled devices may speed delivery and reduce dosing mistakes.
• Know the available device before an emergency; maintain at least 2 doses when repeat dosing may be needed.
• Concentrations and available doses vary by manufacturer; check package instructions.
• The source acknowledges that other drugs or dosing may suit particular circumstances and that drug information changes. Apply current information and clinician judgment rather than treating the chart as exhaustive.

Common board traps

Answer aloud

A child becomes unresponsive in the dental chair. What is the first priority?

Stop treatment, assess airway/breathing/circulation, summon help, and start indicated rescue immediately.

• Activate the office emergency plan and EMS when appropriate; assign roles, retrieve oxygen/AED, and use pediatric resuscitation training.
• Do not delay ventilation or CPR while searching for a diagnosis or drug.
• Document the event, interventions, timing, and transfer; review readiness afterward.

How do you manage apparent syncope without overlooking serious deterioration?

Recline with feet elevated, loosen restrictive clothing, support oxygenation, and monitor recovery.

• Reassess airway/breathing/circulation and the diagnosis if recovery is incomplete or symptoms are atypical.
• The AAPD chart lists ammonia inhalants but supplies no dose or contraindications; do not treat the entry as a blanket recommendation.
• The linked FDA alert concerns unapproved alertness/energy products and airway irritation risks; it does not validate syncope treatment.

What office preparation makes emergency rescue possible?

Maintain a trained team, checked pediatric equipment/drugs, and a practiced emergency plan.

• Review medical history, medications, allergies, and baseline risk before care.
• Use drills, assigned roles, immediately available emergency contacts, oxygen, airway equipment, and AED access.
• Know kit locations, expiry dates, and weight-based calculations; backup/EMS supplements immediate on-site rescue.

Hives, wheeze, and hypotension develop together. What is the immediate drug decision?

Treat as anaphylaxis: activate EMS and give IM epinephrine promptly, with airway/circulatory support and oxygen.

• AAPD chart: 1 mg/mL, 0.01 mg/kg IM, maximum 0.3 mg prepubertal or 0.5 mg teen/adult.
• Mid-outer thigh; if unresponsive, repeat every 5 minutes, total 3 injections, until recovery/EMS arrival; alternate sites.
• Autoinjector: manufacturer instructions. An antihistamine does not replace epinephrine for respiratory/circulatory compromise.

What does the emergency chart specify for acute asthma, and where does it conflict with current guidance?

Oxygen, upright positioning, and albuterol with a spacer; the chart's epinephrine escalation conflicts with current asthma guidance, so verify the protocol before applying it.

• Chart albuterol: 4–8 puffs, repeat every 20 minutes for two additional doses; add a mask if no lip seal.
• Chart epinephrine, if bronchodilator fails or symptoms are severe/multiple: 1 mg/mL, 0.01 mg/kg IM; maximum 0.3 mg prepubertal or 0.5 mg teen/adult; repeat every 5–15 minutes, up to 3 doses.
• GINA does not recommend routine epinephrine for asthma exacerbations without anaphylaxis. Do not apply the chart's epinephrine branch universally; activate EMS as indicated.

AAPD chart; current GINA distinction is sourced in the note.

What naloxone regimen and observation does the chart specify?

Support ventilation first; for severe opioid respiratory depression, chart naloxone is 0.1 mg/kg, up to 2 mg, with repeat dosing as needed.

• IV, IM, or subcutaneous routes; chart cumulative ceiling 10 mg.
• Intranasal product: manufacturer instructions, alternate nostrils for repeats.
• Continue monitoring at least 2 hours after the last dose; this minimum does not by itself establish discharge readiness.
• Arrange advanced care when indicated.

Which flumazenil route is supported by current US product labeling despite the AAPD emergency chart's conflicting entry?

IV only. Do not infer an IM regimen from the chart's alternative-route entry.

• The AAPD chart is a source summary; the product's route and contraindications must remain explicit.
• DailyMed flumazenil prescribing information.

What flumazenil dosing sequence is labeled for pediatric conscious-sedation reversal?

Give 0.01 mg/kg IV, maximum 0.2 mg per dose, over 15 seconds.

• Wait 45 more seconds, then repeat at 60-second intervals if needed, up to four additional doses.
• Cumulative maximum: 0.05 mg/kg or 1 mg, whichever is less.
• The indication names ages 1–17, but the dosing paragraph says greater than one year; preserve that exact-age wording difference.
• Pediatric overdose treatment and repeat treatment for pediatric resedation are not established by this label.
• DailyMed flumazenil prescribing information.

Which seizure-related risks or contraindications matter before flumazenil reversal?

Flumazenil can precipitate seizures; assess dependence, mixed overdose, and why the benzodiazepine was given.

• Do not reverse a benzodiazepine used to control a life-threatening condition such as status epilepticus.
• Contraindications also include hypersensitivity to flumazenil/benzodiazepines and signs of serious cyclic-antidepressant overdose.
• Conscious-sedation reversal is a distinct indication from overdose treatment.
• DailyMed flumazenil prescribing information.

What observation does the AAPD emergency chart require after flumazenil?

Support ventilation and observe for at least two hours after the last dose under the chart.

• Continue assessing breathing and resedation; that minimum alone does not establish readiness for discharge.
• The chart permits repeat doses at one-minute intervals within its cumulative ceiling; current labeling does not establish repeat pediatric treatment for resedation.
• AAPD emergency chart.

What is the chair-side seizure response?

Protect against injury, recline, maintain airway/ventilation, monitor, and involve EMS as indicated.

• For status epilepticus, use the patient's prescribed rescue drug or the chart's benzodiazepine options.
• Diazepam 5 mg/mL: 0.15–0.2 mg/kg IV, maximum 10 mg, repeat once if needed; packaged rectal/nasal products follow their labeling.
• Midazolam 0.2 mg/kg, maximum 10 mg, via IM, intranasal, or IV in this chart.
• CDC first-aid EMS triggers: seizure lasting longer than five minutes, another seizure soon afterward, trouble breathing or waking afterward, injury, or a first seizure. Also call for a seizure in water, pregnancy, or diabetes with loss of consciousness.
• Use the prescribed rescue plan: follow any earlier activation trigger. These are first-aid EMS criteria, not a definition of status epilepticus or a rescue-drug dosing rule.

CDC first-aid guidance; the drug regimens above remain attributed to the AAPD chart.